Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price hit a new 52-week high during trading on Friday. The company traded as high as $353.00 and last traded at $353.00, with a volume of 60 shares changing hands. The stock had previously closed at $338.75.
Genmab A/S Stock Performance
The firm’s 50-day moving average is $316.66 and its 200 day moving average is $284.23. The stock has a market cap of $21.73 billion, a PE ratio of 27.69 and a beta of 0.79. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.
Genmab A/S Company Profile
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing antibody-based medicines for cancer and other serious diseases. Founded in 1999, the company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system and target disease-related cells.
Genmab’s products include Darzalex (daratumumab), developed with Janssen Biotech for certain blood cancers; Epkinly (epcoritamab), developed with AbbVie for certain types of B-cell lymphoma; and Tivdak (tisotumab vedotin), developed with Seagen, now part of Pfizer, for recurrent or metastatic cervical cancer.
Featured Stories
- Five stocks we like better than Genmab A/S
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
